Victor Romanov

Dr. Victor Romanov


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2014 in Archives of Toxicology
Verified
Journal Article
Closed access
PDF file
VRVictor Romanov
Victor Romanov
TWTerry C. Whyard
Terry C. Whyard
WWWayne C. Waltzer
Wayne C. Waltzer
AGArthur P. Grollman
Arthur P. Grollman
TRThomas Rosenquist
Thomas Rosenquist

1 February 2016 in Experimental Cell Research
Verified
Journal Article
Closed access
TWTerry Whyard
Terry Whyard
WWWayne C. Waltzer
Wayne C. Waltzer
DWDouglas Waltzer
Douglas Waltzer
VRVictor Romanov
Victor Romanov

7 September 2011 in Apoptosis
Verified
Journal Article
Closed access
PDF file
VRVictor Romanov
Victor Romanov
TWTerry Whyard
Terry Whyard
RBRadha Bonala
Radha Bonala
FJFrancis Johnson
Francis Johnson
AGArthur Grollman
Arthur Grollman

13 July 2020 in BioTechniques
Verified
Journal Article
Open access
TWTerry Whyard
Terry Whyard
JLJingxuan Liu
Jingxuan Liu
FDFrank S Darras
Frank S Darras
WWWayne C Waltzer
Wayne C Waltzer
VRVictor Romanov
Victor Romanov
3D cancer cell models are suitable for drug evaluation because they more precisely mimic tissue architecture than 2D cultures. To study cytotoxicity of anticancer agents, the most sensitive CellTit... METHOD SUMMARY We describe a simple, reliable bladder cancer 3D organoid culture. We modified the drug response assay for 3D cultures. The widely used assay CellTiter-Glo (Promega, WI, USA) is an e...

28 February 2024 in Cancers
Verified
Journal Article
Open access
PDF file
CDChris Du
Chris Du
WWWayne C. Waltzer
Wayne C. Waltzer
JWJeremy Wilusz
Jeremy Wilusz
MSMassimiliano Spaliviero
Massimiliano Spaliviero
FDFRANK S. DARRAS
FRANK S. DARRAS
VRVictor Romanov
Victor Romanov
The current study aimed to elucidate the regulatory mechanisms of the circRNA hsa_circ_0139697 (circSTAG2(16–25)) in BCa and to consider the opportunity of using circSTAG2(16–25) isolated from BCa patient urine as a marker for disease development prediction. The selection of this circRNA was determined by the special role of its parental gene STAG2 in BCa biology. The circRNA hsa_circ_0139697 was chosen from 25 STAG2 circRNAs due to its differential expression in the urine of BCa patients and healthy volunteers. Higher levels of circSTAG2(16–25) were detected in urine samples obtained from patients with recurrent tumors. A higher expression of circSTAG2(16–25) was also detected in more tumorigenic BCa cell lines. The overexpression of circSTAG2(16–25) in BCa cells induced the elevation of proliferation, motility, and invasion. To study the mechanisms of circSTAG2(16–25) activity, we confirmed that circSTAG2(16–25) can bind miR-145-5p in vitro as was predicted by bioinformatic search. miR-145-5p was shown to suppress some genes that promoted BCa progression. One of these genes, TAGLN2, encodes the protein Transgelin 2, which plays a role in BCa cell motility and invasion. Therefore, the possible mechanism of action of circSTAG2(16–25) could be sponging the tumor suppressor miR-145-5p, which results in activation of TAGLN2. In addition, circSTAG2(16–25) might be considered as a potential biomarker for recurrence prediction.

1 November 2016 in Experimental Cell Research
Verified
Journal Article
Closed access
GRGalina Reshetnikova
Galina Reshetnikova
VSViktoriya S. Sidorenko
Viktoriya S. Sidorenko
TWTerry Whyard
Terry Whyard
MLMark Lukin
Mark Lukin
WWWayne Waltzer
Wayne Waltzer
VRVictor Romanov
Victor Romanov